U.S. Markets close in 3 hrs 29 mins
  • S&P 500

    4,384.68
    -37.62 (-0.85%)
     
  • Dow 30

    34,954.15
    -190.16 (-0.54%)
     
  • Nasdaq

    14,576.81
    -263.91 (-1.78%)
     
  • Russell 2000

    2,178.82
    -38.10 (-1.72%)
     
  • Crude Oil

    71.40
    -0.51 (-0.71%)
     
  • Gold

    1,798.50
    -0.70 (-0.04%)
     
  • Silver

    24.56
    -0.76 (-2.99%)
     
  • EUR/USD

    1.1839
    +0.0031 (+0.2604%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    20.39
    +2.81 (+15.98%)
     
  • GBP/USD

    1.3880
    +0.0056 (+0.4039%)
     
  • USD/JPY

    109.6120
    -0.7630 (-0.6913%)
     
  • BTC-USD

    37,786.27
    -1,443.18 (-3.68%)
     
  • CMC Crypto 200

    895.47
    +19.23 (+2.19%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Amplitude Surgical – Consolidated Annual Sales of €95.5 Million, +10% at Constant Exchange Rates

·4 min read
  • Consolidated annual sales of €95.5 million, +10.0 % at constant exchange rates

  • Activity impacted by the COVID-19 pandemic from October 2020 with a lesser global effect than the previous year

  • Further strong growth in Novastep’s activity: +53.5% at constant exchange rates

VALENCE, France, July 22, 2021--(BUSINESS WIRE)--Regulatory news:

Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) ("Amplitude" or the "Group"), leading French player on the global surgical technology market for lower-limb orthopedics, announces its consolidated sales for its 2020-21 financial year.

Olivier Jallabert, Amplitude Surgical’s CEO, commented: "Amplitude Surgical’s activity was impacted, during a large part of last financial year and on most of its markets, by the public health situation associated with COVID-19, and notably the adoption of restrictions on access to operating rooms. Nevertheless, the Group’s activity increased by 10.0% at constant exchange rates compared with the previous year, which saw an almost total shutdown in activity from mid-March 2020. Moreover, Novastep is continuing its dynamic growth and now accounts for 13.4% of the Group’s sales, with growth of 53.5% at constant exchange rates".

Q4 2020-21 sales

30/06/2021

30/06/2020

Δ actual

Δ constant
currency

€ thousands - IFRS

France

14,002

7,102

97.1%

97.1%

International

7,988

4,735

68.7%

71.3%

of which: subsidiaries

5,977

3,676

62.6%

65.9%

of which: distributors

2,012

1,060

89.8%

90.1%

Total

21,990

11,838

85.8%

86.8%

FY 2020-21 sales

30/06/2021

30/06/2020

Δ actual

Δ constant
currency

€ thousands - IFRS

France

62,391

55,227

13.0%

13.0%

International

33,110

33,059

0.2%

5.2%

of which: subsidiaries

25,192

24,292

3.7%

10.5%

of which: distributors

7,919

8,767

-9.7%

-9.6%

Total

95,502

88,286

8.2%

10.0%

Over its 2020-21 financial year to June 30, 2021, Amplitude Surgical recorded sales of €95.5 million, up 8.2% in actual terms and 10.0% at constant currency. Activity was significantly impacted on most of the Group’s markets from October 2020 by the situation associated with COVID-19, with restrictions on access to operating rooms resulting in the postponement of scheduled surgical procedures. However, the impact was lower for the Group than it was following the almost total shutdown of all activity in the final quarter of the previous year.

During the final quarter of the recently ended financial year, Amplitude Surgical’s activity was up by 86.8% at constant currency.

  • In France, annual sales totaled €62.4 million, up +13%. During the year, activity was negatively impacted from the second quarter by the successive waves of the COVID-19 pandemic, while the previous year the negative impact only affected the final quarter of the year, albeit to a greater extent. France accounted for 64% of total annual sales;

  • The Group’s international activity generated sales of €33.1 million, a slight increase of 0.2% in actual terms and 5.2% at constant currency. The Group’s subsidiaries recorded growth of 10.5% at constant currency to €25.2 million. Subsidiaries’ activity was notably negatively impacted by the public health situation associated with COVID-19 in Brazil and Germany and by the shutdown in the Group’s activity in Japan, while Novastep’s activity in the United States recorded strong growth. Activity with the Group’s distributors fell by 9.6% to €7.9 million;

  • Amplitude Surgical’s direct business (French market and international subsidiaries), which accounts for almost 92% of the Group’s total sales, increased by 12.2% at constant currency;

  • Novastep, innovative solutions for foot and ankle surgery, saw its annual sales further increase to €12.8 million (+53.5% at constant currency). Novastep’s activity accounted for 13.4% of total Group sales.

Next financial press release
2020-21 annual results, on Wednesday October 20, 2021, after market.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2021, Amplitude Surgical had a workforce of 443 employees and recorded sales of nearly 95.5 million euros.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005045/en/

Contacts

Amplitude Surgical
Dimitri Borchtch
CFO
finances@amplitude-surgical.com
+33 (0)4 75 41 87 41

NewCap
Investor Relations
Mathilde Bohin/Thomas Grojean
amplitude@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 94 98